Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Long-Term Investments (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Long-Term Investments for 5 consecutive years, with $111.4 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 38.22% to $111.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.4 million through Dec 2025, up 38.22% year-over-year, with the annual reading at $111.4 million for FY2025, 38.22% up from the prior year.
  • Long-Term Investments for Q4 2025 was $111.4 million at 4D Molecular Therapeutics, up from $67.2 million in the prior quarter.
  • The five-year high for Long-Term Investments was $137.0 million in Q1 2025, with the low at $1.4 million in Q1 2023.
  • Average Long-Term Investments over 5 years is $56.1 million, with a median of $55.9 million recorded in 2024.
  • The sharpest move saw Long-Term Investments tumbled 97.09% in 2023, then skyrocketed 4379.86% in 2024.
  • Over 5 years, Long-Term Investments stood at $67.7 million in 2021, then plummeted by 92.75% to $4.9 million in 2022, then skyrocketed by 123.19% to $11.0 million in 2023, then surged by 635.65% to $80.6 million in 2024, then surged by 38.22% to $111.4 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $111.4 million, $67.2 million, and $123.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.